期刊
CURRENT NEUROPHARMACOLOGY
卷 19, 期 7, 页码 1038-1068出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570159X18666201116145507
关键词
Alzheimer's disease; amyotrophic lateral sclerosis; cerebellar ataxia; huntington disease; neurodegenerative diseases; parkinson's disease; polyglutamine diseases; STUB1; STUB1-associated disease
Neurodegenerative diseases are characterized by the dysfunction and death of neurons, leading to impairments in mobility and cognition. Protein misfolding and aggregation are hypothesized to be the cause of neurotoxicity in these diseases. CHIP may have therapeutic potential for the treatment of multiple neurodegenerative diseases.
Neurodegenerative diseases are characterized by the increasing dysfunction and death of neurons, resulting in progressive impairment of a person's mobility and/or cognition. Protein misfolding and aggregation are commonly hypothesized to cause neurotoxicity and, eventually, neuronal degeneration that are associated with these diseases. Emerging experimental evidence, as well as recent findings from human studies, reveal that the C-terminus of Hsp70 Interacting Protein (CHIP), or STIP1 Homology and U-box containing Protein 1 (STUB1), is a quality control protein involved in neurodegeneration. Here, we review evidence that CHIP interacts with and plays a role in regulating proteins implicated in the pathogenesis of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and polyglutamine diseases, including Huntington's disease and spinocerebellar ataxias. We also review clinical findings identifying mutations in STUB1 as a cause of both autosomal recessive and autosomal dominant forms of cerebellar ataxia. We propose that CHIP modulation may have therapeutic potential for the treatment of multiple neurodegenerative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据